-

Eurofins Expands Its Network of COVID-19 Testing Centers, Including Airports, Ports, Train Stations and Drive-Through Testing Centers, to Enable Convenient and Safe International Travel

LUXEMBOURG--(BUSINESS WIRE)--As international travel for leisure and business continues to gather momentum, easy access to reliable and cost-effective testing is paramount to ensure safe and hassle-free travel experiences. Alongside further vaccination levels, wide-spread testing for SARS-CoV-2 (COVID-19), and sequencing of positive samples, remains crucial to keep the pandemic under control and potentially avoid breeding grounds for further variants. Eurofins (Paris:ERF) remains fully committed to providing holistic testing services for SARS-CoV-2 (COVID-19), not only through home-testing solutions, but also through an extensive, ever-increasing network of testing centers in travel hubs.

To support millions of passengers in the coming months, Eurofins has rapidly expanded its network of strategically located testing centers to about 1000 across Europe, adding around 500 centers to the network within the last 6 weeks. These sampling stations, in about 20 countries across Europe, cover most major business and tourist hubs. Eurofins intends to keep growing this network and provide unparalleled testing coverage to facilitate European and global travel.

Airports play a major role as travel gateways, and Eurofins has established test centers in 40 airports in Europe. Over 30 testing centers in and near major train stations, such as Brussels-south and Paris Roissy airport train stations, and seaports for cruise ship testing, such as Southampton, Athens and Barcelona complement Eurofins’ existing network of testing centers at travel hubs.

Additionally, Eurofins offers drive-through testing centers on several major highways and airport access roads, recently opening drive-through testing centers in the UK and Germany, as well as the deployment of an increasing number of mobile sampling buses across Europe.

Eurofins continues to invest in laboratory capacity and IT solutions to ensure fast turn-around times for test results (as low as 6 hours, in some cases, after receiving the sample at the laboratory for gold standard PCR tests). Eurofins operates an intuitive web portal in 19 languages, to book testing appointments and access testing information.

For more information visit https://www.covid19testing.eu/.

Notes to editor:

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Contacts

Livia Baratta
Investor Relations
Eurofins Scientific SE
ir@eurofins.com

Eurofins Scientific SE

BOURSE:ERF

Release Versions

Contacts

Livia Baratta
Investor Relations
Eurofins Scientific SE
ir@eurofins.com

More News From Eurofins Scientific SE

Eurofins: Weekly Report on Share Repurchases From 20th July to 24th July 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 20/07/2026 FR0014000MR3 3 180 70.8332 CEUX EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 20/07/2026 FR0014000MR3 6 820 70.7743 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 21/07/...

Eurofins Makes Significant Progress in H1 2026 Towards Its Mid-Term 2027 Objectives, With 130bps of Adjusted EBITDA Margin Expansion, Strong Cash Conversion, and 29% EPS Growth

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Financial highlights in H1 2026 Basic EPS8 grew 29% to €1.55 in H1 2026 vs €1.20 in H1 2025, as Eurofins continued to accumulate the operational benefits from the five-year investment programme in its hub and spoke network of laboratories and digitalisation initiatives. Revenues of €3,701m increased by 2.5% as reported including a 2.9% headwind from foreign currency, and 2.7% organically13. Organic growth13 improved as the half...

Eurofins Scientific SE: Weekly Report on Share Repurchases from 13th July to 17th July 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Weekly report on share repurchases from 13th July to 17th July 2026   Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 13/07/2026 FR0014000MR3 15 000 69.1984 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 13/07...
Back to Newsroom